RESUMO
Development of new drug therapy is difficult for large companies and almost unheard of by individuals. This autobiographical account of the development of the tetracycline fiber delivery system for periodontal therapy (Actisite) relates experiences of a scientist between 1976 and 1994 which lead to FDA approval. In this account, the author acknowledges some of the key people, companies and institutions who were important in this development, makes observations concerning the process itself and offers suggestions for those who might consider commercial development of a scientific concept.
Assuntos
Sistemas de Liberação de Medicamentos/história , Doenças Periodontais/tratamento farmacológico , Tetraciclina/administração & dosagem , Aprovação de Drogas/história , Sistemas de Liberação de Medicamentos/instrumentação , História do Século XX , Humanos , Doenças Periodontais/história , Tetraciclina/história , Estados Unidos , United States Food and Drug Administration , Compostos de VinilaAssuntos
Osso e Ossos/análise , Fósseis , Paleontologia , Tetraciclina/história , Adolescente , Adulto , Arqueologia , Criança , Pré-Escolar , Feminino , História Medieval , Humanos , Masculino , Pessoa de Meia-Idade , Sudão , Tetraciclina/análiseRESUMO
Nubian bone recovered from an X-group cemetery (A.D. 350 to 550) exhibits a pattern of fluorescence identical to that of modern tetracycline-labeled bone. When it is viewed under ultraviolet light at 490 angstroms, fluorophors are visible as a characteristic yellow-green fluorescence on surfaces that were actively mineralizing at the time of exposure. Contamination of stored grains provided the proper environment for cultivation of tetracycline-producing Streptomycetes. Evidence for exposure to antibiotics in an archeological population is relevant to studies of the evolution of R factors and to the interpretation of health and disease within the population.